Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
News & Analysis: Chimerix
This once-promising clinical-stage company is trying to prove that it's not dead yet, but investors remain skeptical.
Analysts and investors continue to warm up to the company's shares after their December implosion.
Shares are recovering today from their massive sell-off, but the company's near-term future remains a mystery.
Here's why a brand management company, a marine shipper, and a biopharmaceutical were the worst-performing small company stocks in 2015.
Even as the market traded quietly, these stocks fell harder. Find out why.
The biopharma's shares imploded after the company's lead product candidate missed its primary endpoint in a late-stage study.
Looking for a few growth stocks that could power your portfolio higher? Our contributors think these 3 names deserve a look.
Chimerix shares rally following the close of its share offering. Find out what shareholders should have their eyes on instead.
Chimerix shares soar following a successful cash-raising effort. Find out what investors should really be watching with Chimerix going forward.